LT 1001

Drug Profile

LT 1001

Alternative Names: SDE; Sebocoyl dinalbuphine ester

Latest Information Update: 03 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Lumosa Therapeutics
  • Class Analgesics; Esters; Ethers; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid kappa receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Pain

Most Recent Events

  • 03 Aug 2017 LT 1001 is still in phase-II/III development for Pain in Taiwan (Lumosa Therapeutics website, August 2017)
  • 03 Aug 2017 LT 1001 is available for licensing as of 03 Aug 2017. www.lumosa.com
  • 01 Apr 2015 Lumosa Therapeutics completes a phase II/III trial in Pain in Taiwan (NCT02468128)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top